AUB ScholarWorks

Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection

Show simple item record

dc.contributor.author Inati A.
dc.contributor.author Taher A.
dc.contributor.author Ghorra S.
dc.contributor.author Koussa S.
dc.contributor.author Taha M.
dc.contributor.author Aoun E.
dc.contributor.author Sharara A.I.
dc.contributor.editor
dc.date Aug-2005
dc.date.accessioned 2017-10-05T15:41:59Z
dc.date.available 2017-10-05T15:41:59Z
dc.date.issued 2005
dc.identifier 10.1111/j.1365-2141.2005.05645.x
dc.identifier.isbn
dc.identifier.issn 00071048
dc.identifier.uri http://hdl.handle.net/10938/18274
dc.description.abstract Thalassaemia patients with genotype 1 or 4 chronic hepatitis C virus (HCV) infection were randomised to receive peginterferon alpha-2a 180 mg-week ribavirin for 48 weeks. Primary efficacy variable was sustained viral response (SVR) at 72 weeks. Thirty-two patients were evaluated; 20 enrolled. Baseline characteristics were comparable. SVR occurred in four of 12 and five of eight patients in the monotherapy and combination groups (30percent and 62·5percent; P = 0·19), respectively. Undetectable RNA at 12 weeks and age 18 years were associated with improved SVR (P 0·05). Transfusion requirements rose by 34percent in the combination arm (P = 0·08). Peginterferon-ribavirin was effective in thalassaemics with HCV and moderate iron overload. © 2005 Blackwell Publishing Ltd.
dc.format.extent
dc.format.extent Pages: (644-646)
dc.language English
dc.publisher OXFORD
dc.relation.ispartof Publication Name: British Journal of Haematology; Publication Year: 2005; Volume: 130; no. 4; Pages: (644-646);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection
dc.type Article
dc.contributor.affiliation Inati, A., Chronic Care Center, Lebanese American University, Beirut, Lebanon
dc.contributor.affiliation Taher, A., Chronic Care Center, Lebanese American University, Beirut, Lebanon, Department of Internal Medicine, American University of Beirut Medical Center, Lebanese American University, Beirut, Lebanon
dc.contributor.affiliation Ghorra, S., School of Pharmacy, Lebanese American University, Beirut, Lebanon
dc.contributor.affiliation Koussa, S., Chronic Care Center, Lebanese American University, Beirut, Lebanon
dc.contributor.affiliation Taha, M., School of Pharmacy, Lebanese American University, Beirut, Lebanon
dc.contributor.affiliation Aoun, E., Department of Internal Medicine, American University of Beirut Medical Center, Lebanese American University, Beirut, Lebanon
dc.contributor.affiliation Sharara, A.I., Department of Medicine, Box 16-B, American University of Beirut Medical Center, PO Box 11-0236, Riad El Solh 110, 72020, Beirut, Lebanon, Department of Internal Medicine, American University of Beirut Medical Center, Lebanese American University, Beirut, Lebanon
dc.contributor.authorAddress Sharara, A.I.; Department of Medicine, Box 16-B, American University of Beirut Medical Center, PO Box 11-0236, Riad El Solh 110, 72020, Beirut, Lebanon; email: as08@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision
dc.contributor.authorEmail as08@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Inati, A
dc.contributor.authorInitials Taher, A
dc.contributor.authorInitials Ghorra, S
dc.contributor.authorInitials Koussa, S
dc.contributor.authorInitials Taha, M
dc.contributor.authorInitials Aoun, E
dc.contributor.authorInitials Sharara, AI
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Sharara, AI (reprint author), American Univ, Beirut Med Ctr, Chron Care Ctr, POB 11-0236,Riad El Solh 110, Beirut 72020, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Ceci A, 2002, BRIT J HAEMATOL, V118, P330, DOI 10.1046-j.1365-2141.2002.03554.x; Dieterich DT, 2003, AM J GASTROENTEROL, V98, P2491, DOI 10.1016-j.amjgastroenterol.2003.08.006; DIMARCO V, 1992, HAEMATOLOGICA, V77, P502; DONOHUE SM, 1993, BRIT J HAEMATOL, V83, P491, DOI 10.1111-j.1365-2141.1993.tb04676.x; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056-NEJMoa020047; Hamidah A, 2002, Med J Malaysia, V57, P353; Li CK, 2002, BRIT J HAEMATOL, V117, P755, DOI 10.1046-j.1365-2141.2002.03491.x; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016-S0140-6736(01)06102-5; Mencacci A, 1997, J INFECT DIS, V175, P1467; Sherker AH, 2003, HEPATOLOGY, V37, P223, DOI 10.1053-jhep.2003.50037; Sievert W, 2002, AM J GASTROENTEROL, V97, P982; Telfer PT, 1997, BRIT J HAEMATOL, V98, P850, DOI 10.1046-j.1365-2141.1997.2953112.x
dc.description.citedCount 39
dc.description.citedTotWOSCount 30
dc.description.citedWOSCount 29
dc.format.extentCount 3
dc.identifier.articleNo
dc.identifier.coden BJHEA
dc.identifier.pubmedID 16098081
dc.identifier.scopusID 24944502327
dc.identifier.url
dc.publisher.address 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Br. J. Haematol.
dc.relation.ispartOfIssue 4
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle British Journal of Haematology
dc.relation.ispartofPubTitleAbbr Br. J. Haematol.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 130
dc.source.ID WOS:000230886600022
dc.type.publication Journal
dc.subject.otherAuthKeyword Haemoglobinopathies
dc.subject.otherAuthKeyword Iron overload
dc.subject.otherAuthKeyword Siderosis
dc.subject.otherAuthKeyword transfusion
dc.subject.otherChemCAS deferiprone, 30652-11-0
dc.subject.otherChemCAS iron, 14093-02-8, 53858-86-9, 7439-89-6
dc.subject.otherChemCAS peginterferon alpha2a, 198153-51-4
dc.subject.otherChemCAS ribavirin, 36791-04-5
dc.subject.otherChemCAS alpha2a interferon, 76543-88-9
dc.subject.otherChemCAS Antiviral Agents
dc.subject.otherChemCAS Interferon Alfa-2a, 76543-88-9
dc.subject.otherChemCAS peginterferon alfa-2a
dc.subject.otherChemCAS Polyethylene Glycols
dc.subject.otherChemCAS Ribavirin, 36791-04-5
dc.subject.otherChemCAS RNA, Viral
dc.subject.otherIndex deferiprone
dc.subject.otherIndex iron
dc.subject.otherIndex iron chelating agent
dc.subject.otherIndex peginterferon alpha2a
dc.subject.otherIndex ribavirin
dc.subject.otherIndex alpha2a interferon
dc.subject.otherIndex antivirus agent
dc.subject.otherIndex macrogol derivative
dc.subject.otherIndex peginterferon alfa-2a
dc.subject.otherIndex peginterferon alpha2a
dc.subject.otherIndex ribavirin
dc.subject.otherIndex virus RNA
dc.subject.otherIndex adolescent
dc.subject.otherIndex adult
dc.subject.otherIndex anemia
dc.subject.otherIndex article
dc.subject.otherIndex chronic hepatitis
dc.subject.otherIndex clinical article
dc.subject.otherIndex clinical trial
dc.subject.otherIndex controlled clinical trial
dc.subject.otherIndex controlled study
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug tolerability
dc.subject.otherIndex female
dc.subject.otherIndex genotype
dc.subject.otherIndex granulocytopenia
dc.subject.otherIndex hepatitis C
dc.subject.otherIndex Hepatitis C virus
dc.subject.otherIndex human
dc.subject.otherIndex intermethod comparison
dc.subject.otherIndex iron overload
dc.subject.otherIndex leukopenia
dc.subject.otherIndex male
dc.subject.otherIndex monotherapy
dc.subject.otherIndex neutropenia
dc.subject.otherIndex outcome assessment
dc.subject.otherIndex polypharmacy
dc.subject.otherIndex priority journal
dc.subject.otherIndex randomized controlled trial
dc.subject.otherIndex RNA analysis
dc.subject.otherIndex school child
dc.subject.otherIndex thalassemia major
dc.subject.otherIndex transfusion
dc.subject.otherIndex treatment response
dc.subject.otherIndex beta thalassemia
dc.subject.otherIndex blood
dc.subject.otherIndex blood transfusion
dc.subject.otherIndex child
dc.subject.otherIndex drug combination
dc.subject.otherIndex follow up
dc.subject.otherIndex genetics
dc.subject.otherIndex hepatitis C
dc.subject.otherIndex Lebanon
dc.subject.otherIndex virology
dc.subject.otherIndex virus load
dc.subject.otherIndex Adolescent
dc.subject.otherIndex Adult
dc.subject.otherIndex Antiviral Agents
dc.subject.otherIndex beta-Thalassemia
dc.subject.otherIndex Blood Transfusion
dc.subject.otherIndex Child
dc.subject.otherIndex Drug Therapy, Combination
dc.subject.otherIndex Female
dc.subject.otherIndex Follow-Up Studies
dc.subject.otherIndex Hepacivirus
dc.subject.otherIndex Hepatitis C, Chronic
dc.subject.otherIndex Humans
dc.subject.otherIndex Interferon Alfa-2a
dc.subject.otherIndex Lebanon
dc.subject.otherIndex Male
dc.subject.otherIndex Polyethylene Glycols
dc.subject.otherIndex Ribavirin
dc.subject.otherIndex RNA, Viral
dc.subject.otherIndex Viral Load
dc.subject.otherKeywordPlus INTERFERON-ALPHA
dc.subject.otherKeywordPlus BETA-THALASSEMIA
dc.subject.otherKeywordPlus PLUS RIBAVIRIN
dc.subject.otherKeywordPlus IRON OVERLOAD
dc.subject.otherKeywordPlus THERAPY
dc.subject.otherWOS Hematology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account